

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number
WO 2004/111210 A1

(51) International Patent Classification⁷: **C12N 5/06.**
A61K 35/12, 38/17, 35/30

(21) International Application Number:
PCT/IL2004/000507

(22) International Filing Date: 13 June 2004 (13.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
156430 12 June 2003 (12.06.2003) IL
159226 7 December 2003 (07.12.2003) IL

(71) Applicant (for all designated States except US): **Yeda Research & Development Co.Ltd** [IL/IL]; Weizmann Institute of Science, POBox 95, 76100 REHOVOT (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHEBATH, Judith** [IL/IL]; Weizmann Institute, 76100 REHOVOT (IL).

REVEL, Michel [IL/IL]; Weizmann Institute, 76100 REHOVOT (IL). **LONAI, Peter** [IL/IL]; Weizmann Institute, 76100 REHOVOT (IL).


(74) Agent: **EINAV, Henry**; INTER-LAB LTD. Science Based Industrial Park, Kiryat Weizmann, 76110 NESS ZIONA (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, ...)

[Continued on next page]

(54) Title: **ENHANCEMENT OF OLIGODENDROCYTE DIFFERENTIATION**



(57) Abstract: The present invention is generally in the field of neurological diseases and disorders, particular in the field of neurodegenerative diseases in which the myelin cover of nerves is lost. IL6R/IL6 chimera is used to promote the formation of oligodendrocytes from embryonic stem cells for treatment of neurodegenerative diseases or posttraumatic nerve damage.

BEST AVAILABLE COPY

WO 2004/111210 A1